{"transactions":[{"id":4615627,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Science Enterprises plc","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"former 10% owner"}}],"security":"Ordinary Shares","published_at":"2026-09-11T15:00:41.000Z","date":"2026-09-09","kind":"other","planned":false,"acquired":false,"shares":8797770,"price":0.111,"value":976552.47,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Ordinary Shares may be represented by American Depositary Shares, each of which represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement between Barinthus Biotherapeutics plc (the \"Issuer\") and Clywedog Therapeutics, Inc., the Issuer's board of directors has determined that each of the Issuer's outstanding Ordinary Shares (represented by American Depositary Shares) will be converted into the right to receive 0.111 shares of Beacon Topco, Inc.'s common stock, plus cash in lieu of any fractional shares resulting from the exchange, in accordance with the scheme of arrangement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001856079-26-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1856079/000185607926000002/primary_doc.xml","form_type":"4/A","original_submission_date":"2021-05-06"}},{"id":1029000,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Science Enterprises plc","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-10-01T17:07:57.000Z","date":"2025-09-30","kind":"purchase","planned":false,"acquired":true,"shares":200000,"price":3.2,"value":640000.0,"ownership":{"direct":true},"balance_after":4955388,"source":{"system":"sec-edgar","filing":"0001856079-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835597/000185607925000003/primary_doc.xml","form_type":"4"}},{"id":1544248,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Science Enterprises plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-09T21:24:38.000Z","date":"2022-05-10","kind":"purchase","planned":false,"acquired":true,"shares":879970,"price":12,"value":10559640.0,"ownership":{"direct":true},"balance_after":4755388,"source":{"system":"sec-edgar","filing":"0000950170-24-043058","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024043058/ownership.xml","form_type":"4/A","original_submission_date":"2022-05-10"}},{"id":2275752,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Science Enterprises plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred stock","published_at":"2022-05-10T22:42:49.000Z","date":"2022-05-10","kind":"exercise","acquired":false,"shares":1575572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1547713},"source":{"system":"sec-edgar","filing":"0000899243-22-017488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1835597/000089924322017488/doc4.xml","form_type":"4"}},{"id":2275751,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Science Enterprises plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Preferred stock","published_at":"2022-05-10T22:42:49.000Z","date":"2022-05-10","kind":"exercise","acquired":false,"shares":962884,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":945859},"source":{"system":"sec-edgar","filing":"0000899243-22-017488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1835597/000089924322017488/doc4.xml","form_type":"4"}},{"id":2275750,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Science Enterprises plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred stock","published_at":"2022-05-10T22:42:49.000Z","date":"2022-05-10","kind":"exercise","acquired":false,"shares":1285720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1262986},"source":{"system":"sec-edgar","filing":"0000899243-22-017488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1835597/000089924322017488/doc4.xml","form_type":"4"}},{"id":2275749,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Science Enterprises plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-10T22:42:49.000Z","date":"2022-05-10","kind":"exercise","acquired":true,"shares":1547713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."}],"balance_after":3875418,"source":{"system":"sec-edgar","filing":"0000899243-22-017488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835597/000089924322017488/doc4.xml","form_type":"4"}},{"id":2275748,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Science Enterprises plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-10T22:42:49.000Z","date":"2022-05-10","kind":"exercise","acquired":true,"shares":945859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."}],"balance_after":2327705,"source":{"system":"sec-edgar","filing":"0000899243-22-017488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835597/000089924322017488/doc4.xml","form_type":"4"}},{"id":2275747,"issuer":{"id":6253,"kind":"organization","name":"PepGen Inc."},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Science Enterprises plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-10T22:42:49.000Z","date":"2022-05-10","kind":"exercise","acquired":true,"shares":1262986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 10, 2022, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock (collectively, the \"Preferred Stock\") converted into shares of Common Stock of the Issuer on a 1.018-for-1 basis without payment of further consideration upon closing of the initial public offering of the Issuer's Common Stock. The shares of Preferred Stock had no expiration date."}],"balance_after":1381846,"source":{"system":"sec-edgar","filing":"0000899243-22-017488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835597/000089924322017488/doc4.xml","form_type":"4"}},{"id":2724708,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Sciences Innovation plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B preferred shares","published_at":"2021-05-06T20:25:28.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":1661184,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"shares","element":"transactionShares","label":"F4","text":"The number of shares reported reflects the conversion set out in Footnote (3)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The number of shares reported reflects the conversion set out in Footnote (3)."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1661184},"source":{"system":"sec-edgar","filing":"0001104659-21-062421","document":"tm2115262-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465921062421/tm2115262-1_4seq1.xml","form_type":"4"}},{"id":2724707,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Sciences Innovation plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A redeemable convertible preferred shares","published_at":"2021-05-06T20:25:28.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":1704444,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"shares","element":"transactionShares","label":"F4","text":"The number of shares reported reflects the conversion set out in Footnote (3)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The number of shares reported reflects the conversion set out in Footnote (3)."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1704444},"source":{"system":"sec-edgar","filing":"0001104659-21-062421","document":"tm2115262-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465921062421/tm2115262-1_4seq1.xml","form_type":"4"}},{"id":2724706,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Sciences Innovation plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2021-05-06T20:25:28.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":4832142,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"shares","element":"transactionShares","label":"F4","text":"The number of shares reported reflects the conversion set out in Footnote (3)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The number of shares reported reflects the conversion set out in Footnote (3)."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":4832142},"source":{"system":"sec-edgar","filing":"0001104659-21-062421","document":"tm2115262-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465921062421/tm2115262-1_4seq1.xml","form_type":"4"}},{"id":2724705,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Sciences Innovation plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"American Depositary Shares","published_at":"2021-05-06T20:25:28.000Z","date":"2021-05-04","kind":"purchase","acquired":true,"shares":600000,"price":17,"value":10200000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Each American Depositary Share represents one ordinary share."}],"balance_after":8797770,"source":{"system":"sec-edgar","filing":"0001104659-21-062421","document":"tm2115262-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465921062421/tm2115262-1_4seq1.xml","form_type":"4"}},{"id":2724704,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Sciences Innovation plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2021-05-06T20:25:28.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":1661184,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of whicb currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."}],"balance_after":8197770,"source":{"system":"sec-edgar","filing":"0001104659-21-062421","document":"tm2115262-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465921062421/tm2115262-1_4seq1.xml","form_type":"4"}},{"id":2724703,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Sciences Innovation plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2021-05-06T20:25:28.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":1704444,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of whicb currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."}],"balance_after":6536586,"source":{"system":"sec-edgar","filing":"0001104659-21-062421","document":"tm2115262-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465921062421/tm2115262-1_4seq1.xml","form_type":"4"}},{"id":2724702,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":74731,"kind":"organization","name":"Oxford Science Enterprises plc","position":1,"cik":"0001856079","reported_name":"Oxford Sciences Innovation plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2021-05-06T20:25:28.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":4832142,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of whicb currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each ordinary share, Series A redeemable convertible preferred share and Series B preferred share were converted into Ordinary Shares on a one-for-309 basis immediately prior to the closing ofVaccilech plc's (the \"Issuer\") initial public offering without payment of consideration. None of the ordinary shares, Series A redeemable convertible preferred share and Series B preferred shares had an expiration date."}],"balance_after":4832142,"source":{"system":"sec-edgar","filing":"0001104659-21-062421","document":"tm2115262-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465921062421/tm2115262-1_4seq1.xml","form_type":"4"}}]}